• DOI:10.1152/AJPHEART.00937.2006
• Corpus ID: 33821639

Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1-7).

@article{Grobe2007PreventionOA,
  title={Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1-7).},
  author={Justin L. Grobe and Adam P. Mecca and Melissa Lingis and Vinayak Shenoy and Tonya A. Bolton and Juline M. Machado and Robert C. Speth and Mohan K. Raizada and Michael J. Katovich},
  journal={American journal of physiology. Heart and circulatory physiology},
  year={2007},
  volume={292 2},
  pages={
          H736-42
        }
}

• J. Grobe, A. Mecca, +6 authors M. Katovich
• Published 1 February 2007
• Biology, Medicine
• American journal of physiology. Heart and circulatory physiology

Cardiac remodeling, which typically results from chronic hypertension or following an acute myocardial infarction, is a major risk factor for the development of heart failure and, ultimately, death. The renin-angiotensin system (RAS) has previously been established to play an important role in the progression of cardiac remodeling, and inhibition of a hyperactive RAS provides protection from cardiac remodeling and subsequent heart failure. Our previous studies have demonstrated that overexpression of angiotensin-converting enzyme 2 (ACE2) prevents cardiac remodeling and hypertrophy during chronic infusion of angiotensin II (ANG II). This, coupled with the knowledge that ACE2 is a key enzyme in the formation of ANG-(1-7), led us to hypothesize that chronic infusion of ANG-(1-7) would prevent cardiac remodeling induced by chronic infusion of ANG II. Infusion of ANG II into adult Sprague-Dawley rats resulted in significantly increased blood pressure, myocyte hypertrophy, and midmyocardial interstitial fibrosis. Coinfusion of ANG-(1-7) resulted in significant attenuations of myocyte hypertrophy and interstitial fibrosis, without significant effects on blood pressure. In a subgroup of animals also administered [d-Ala(7)]-ANG-(1-7) (A779), an antagonist to the reported receptor for ANG-(1-7), there was a tendency to attenuate the antiremodeling effects of ANG-(1-7). Chronic infusion of ANG II, with or without coinfusion of ANG-(1-7), had no effect on ANG II type 1 or type 2 receptor binding in cardiac tissue. Together, these findings indicate an antiremodeling role for ANG-(1-7) in cardiac tissue, which is not mediated through modulation of blood pressure or altered cardiac angiotensin receptor populations and may be at least partially mediated through an ANG-(1-7) receptor.